Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration

Approval of B-cell-depleting therapies signifies an important advance in the treatment of multiple sclerosis (MS). However, it is unclear whether the administration route of anti-CD20 monoclonal antibodies (mAbs) alters tissue distribution patterns and subsequent downstream effects. This study aimed...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Julia Baguña Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-07-01
coleção:	Frontiers in Immunology
Assuntos:	ofatumumab ocrelizumab subcutaneous intravenous multiple sclerosis distribution
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.814064/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!